Our objective was to evaluate the efficacy of cold coagulation in the treatment of cervical intraepithelial neoplasia. The study design consisted of a retrospective review of case records of all women treated with cold coagulation from the colposcopy clinics inception in 1980 to 1994. A total of 725 women received treatment with cold coagulation. All grades of CIN were treated. 632 (87.1 %) had long term negative follow up. 93(12.6%) of patients had abnormal cytological follow up, but only 45(6.2%) required re-treatment. Within the first year after treatment 52(7.1%) patients presented with persistent cytological abnormalities, 32(4.4%) required repeated treatment for persistent dyskaryosis. 41(5.6%) ofpatients had recurrent cytological abnormalities, 13(1.8 %) required repeated treatment. Recurrence developed between two and 12 years from initial treatment. One case of cervical carcinoma following treatment with cold coagulation was recorded. Our data suggest that cold coagulation appears to be safe, efficient treatment for cervical intraepithelial neoplasia. 
INTRODUCTION
Cold coagulation is one ofmany ablative methods designed to destroy an abnormal transformation zone. It has been successfully used to treat noninvasive cervical conditions since 1966. This treatment method was introduced to clinical practice for the first time by Kurt Semm;' it became a popular method for the treatment of CIN. In the 1980s it was the second most popular treatment modality, for CIN in the UK. It Treatment was preceded by punch biopsy. All grades of CIN were treated in the same way by application of the Semm coagulator (WISAP, Germany) to the cervix. The probe heated to 120°C was applied to each part of the cervix for 30-40 sec. ensuring that the whole transformation zone was destroyed beyond the limit of acetowhite epithelium. All patients were advised to apply Sultrin cream (Janssen-Cilag) vaginally, nightly for one week and to avoid intercourse and use of tampons for three weeks. Initially treatment was performed during the second visit, but as experience developed a "see, biopsy and treat" policy was employed, with only less experienced or trainee colposcopists awaiting biopsy results before treatment. The pattern of follow up changed over the years of study, but all patients were followed up by at least cytological assessment. This was initially performed at the 3-4 months follow-up visit. colposcopy clinics in North West. The recurrence rate following treatment with cold coagulation is very low, 5.6% in our study, with mainly low grade abnormalities being found at follow-up. Not surprisingly we found the highest level of treatment failure among CIN III lesions which accounted for 42% of referred cases. It is our opinion that previous treatment to the cervix, as a factor changing its anatomy is a contraindication for cold coagulation treatment. The only case of invasive cancer of cervix following treatment with cold coagulation occurred in a woman who had previously had treatment to her cervix, which distorted the anatomy preventing the full lesion from being amenable to cold coagulation, although it should be noted that several attempts had been made to excise persistent abnormalities before she developed invasive disease. During the study period there were 10 cases of carcinoma of cervix diagnosed on histopathology as a result of excisional biopsies, which had not been colposcopically detected. All of these patients had unsatisfactory colposcopy, therefore had been considered unsuitable for treatment with cold coagulation and were treated by excislonal techniques. We have not encountered unexpected histopathology results of microinvasive or invasive carcinoma from biopsies taken prior to the cold coagulation treatment.
